HL Protocol Treatment Modifications Table

Preferred Label : HL Protocol Treatment Modifications Table;

NCIt synonyms : Hodgkin's Lymphoma Protocol Treatment Modifications Table;

NCIt related terms : Protocol Treatment Modifications Table;

NCIt definition : Terminology created by EVS and PCDC to support the HL Protocol Treatment Modifications Table.;

NCI Metathesaurus CUI : CL1778640;

Details

Origin ID

C186327;

UMLS CUI

C5670457;

Semantic type(s)
- Intellectual Product [UMLS semantic type]
concept_is_in_subset
- HL Table Terminology [NCIt concept]
- PCDC Terminology [NCIt concept]
subset_includes_concept
- Age in Days of Protocol Treatment Modification [NCIt concept]
- Agent Substitution [NCIt concept]
- Allergic Reaction [NCIt concept]
- Bendamustine [NCIt concept]
- Bleomycin [NCIt concept]
- Brentuximab Vedotin [NCIt concept]
- Busulfan [NCIt concept]
- Carboplatin [NCIt concept]
- Cardiotoxicity [NCIt concept]
- Carmustine [NCIt concept]
- Change Reason [NCIt concept]
- Chemoimmunotherapy [NCIt concept]
- Chemotherapy [NCIt concept]
- Cisplatin [NCIt concept]
- Clinical Indication [NCIt concept]
- Cyclophosphamide [NCIt concept]
- Cytarabine [NCIt concept]
- Dacarbazine [NCIt concept]
- Dexamethasone [NCIt concept]
- Disease Phase [NCIt concept]
- Disease Phase Number [NCIt concept]
- Disease Progression [NCIt concept]
- Dose Reduced [NCIt concept]
- Doxorubicin [NCIt concept]
- Drug Not Available [NCIt concept]
- Drug Withdrawn [NCIt concept]
- Endocrine Therapy Toxicity [NCIt concept]
- Etoposide [NCIt concept]
- Etoposide Phosphate [NCIt concept]
- Fludarabine [NCIt concept]
- Gastrointestinal Toxicity [NCIt concept]
- Gemcitabine [NCIt concept]
- Hematologic Toxicity [NCIt concept]
- Hepatic Toxicity [NCIt concept]
- Ifosfamide [NCIt concept]
- Immunotherapy [NCIt concept]
- Immunotoxicity [NCIt concept]
- Infection [NCIt concept]
- Infusion Related Toxicity [NCIt concept]
- Initial Diagnosis [NCIt concept]
- Mechlorethamine [NCIt concept]
- Medication Course Number [NCIt concept]
- Melphalan [NCIt concept]
- Methotrexate [NCIt concept]
- Modification Type [NCIt concept]
- Mucositis [NCIt concept]
- Musculoskeletal Toxicity [NCIt concept]
- Neuropathy [NCIt concept]
- Neutropenia [NCIt concept]
- New Agent Addition [NCIt concept]
- Nivolumab [NCIt concept]
- No Reason Given [NCIt concept]
- Non-Hematologic Toxicity [NCIt concept]
- On Protocol Therapy [NCIt concept]
- Original Agent [NCIt concept]
- Other [NCIt concept]
- PCDC Subject Identifier [NCIt concept]
- Patient Noncompliance [NCIt concept]
- Pembrolizumab [NCIt concept]
- Pre-Existing Organ Dysfunction [NCIt concept]
- Prednisone [NCIt concept]
- Procarbazine [NCIt concept]
- Protocol Treatment Course [NCIt concept]
- Pulmonary Toxicity [NCIt concept]
- Radiation Therapy [NCIt concept]
- Recurrent Disease [NCIt concept]
- Refractory [NCIt concept]
- Renal Toxicity [NCIt concept]
- Scheduling Issue [NCIt concept]
- Skin Rash [NCIt concept]
- Surgical Complication [NCIt concept]
- Thiotepa [NCIt concept]
- Thrombocytopenia [NCIt concept]
- Toxicity Details [NCIt concept]
- Toxicity due to Psychiatric Drugs [NCIt concept]
- Treatment Modification Rationale [NCIt concept]
- Treatment on Hold [NCIt concept]
- Unknown [NCIt concept]
- Vinblastine [NCIt concept]
- Vincristine [NCIt concept]
- Vinorelbine [NCIt concept]
- Yes [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients